Biogen Inc (NASDAQ:BIIB)
| 301.23 Delayed Data As of Apr 03 |  -3.96 / -1.30%Today’s Change | 215.78 Today|||52-Week Range 374.99 | +1.52% Year-to-Date |
Latest BIIB News | Press Releases
| 3 Warren Buffett Stocks I Absolutely, Positively Wouldn't Buy Right Now Apr 05 / MotleyFool.com - Paid Partner Content | 4 Reasons Drug Stocks Are a Buy Right Now Mar 30 / MotleyFool.com - Paid Partner Content |
| Why Gilead Sciences Is the Hottest Stock to Buy Today Apr 04 / MotleyFool.com - Paid Partner Content | Bristol Myers Squibb's Multiple Sclerosis Drug, a Potential Blockbuster, Wins FDA Approval Mar 26 / MotleyFool.com - Paid Partner Content |
| Better Buy: Gilead Sciences vs. Biogen Apr 03 / MotleyFool.com - Paid Partner Content | 4 Reasons Biotech Stocks Are a Buy Right Now Mar 25 / MotleyFool.com - Paid Partner Content |
| Why Biogen Shares Rose 2.59% in March Apr 02 / MotleyFool.com - Paid Partner Content | Better Buy: AbbVie vs. Biogen Mar 24 / MotleyFool.com - Paid Partner Content |
| So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature Apr 01 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 304.47 |
| Today’s open | 303.70 |
| Day’s range | 296.81 - 311.52 |
| Volume | 1,422,849 |
| Average volume (3 months) | 1,982,200 |
| Market cap | $53.0B |
Data as of 4:32pm ET, 04/03/2020
Growth & Valuation
| Earnings growth (last year) | +45.55% |
| Earnings growth (this year) | -2.99% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +5.49% |
| P/E ratio | 9.6 |
| Price/Sales | 4.37 |
| Price/Book | 3.97 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | -9.49 | -3.48% |
| BMRNBiomarin Pharmaceuti... | -1.85 | -2.15% |
| MRNAModerna Inc | +1.64 | +4.94% |
| EXASExact Sciences Corp | -1.85 | -3.21% |
Data as of 4:07pm ET, 04/03/2020
Financials
| Next reporting date | April 22, 2020 |
| EPS forecast (this quarter) | $7.76 |
| Annual revenue (last year) | $12.7B |
| Annual profit (last year) | $5.9B |
| Net profit margin | 46.32% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
